For pharmaceutical companies developing insulin, GLP-1, and FSH therapies, the rising incidence of chronic diseases has intensified demand for precision dosing devices that reduce clinical workload, minimize needle-stick injuries, and prevent medication waste. Wuxi NEST Biotechnology Co., Ltd., operating under the brand NEST, entered the pharmaceutical packaging materials sector in 2018 and has since built a one-stop provider model spanning injection and inhalation drug delivery technologies. Among its most clinically relevant offerings is the pairing of pre-sterilized RTU Cartridges with a broad pen-injector assembly portfolio engineered specifically for self-administration in chronic disease management, including diabetes and growth hormone deficiency treatment.
RTU Cartridges: Engineered for Pre-Sterilized Clinical Assembly
NEST's RTU Cartridges are positioned as next-generation parenteral packaging, constructed from borosilicate glass and finished with a proprietary cross-linked siliconization technology that delivers stable gliding performance inside syringes and cartridges. The cartridges are available in 1.5mL, 2.0mL, and 3.0mL formats, allowing flexibility for different dosing volumes required in pen-injector assemblies. Sterilization is achieved through moist heat sterilization capabilities rated at SAL 10⁻⁶, and NEST has been identified as a provider of the first moist heat sterilized cartridges in China. Every cartridge batch undergoes 100% multi-angle CCD camera inspection, supporting the consistent quality demanded by clinical-grade drug-device combinations.
Pen Injector Portfolio Built for Chronic Disease Self-Administration
NEST's Injection Pen Line is built around self-administration solutions for chronic diseases such as diabetes and growth hormone deficiency, and includes eight distinct pen injector configurations designed to work with pre-sterilized cartridge assemblies.
Disposable Pen Injector
This is a three-step liquid medicine injection device designed to address the high cost of reusable devices and the risk of cross-contamination. It offers customization in appearance and dosage—available in 36/37/50/60/74/75/80 units—backed by professional data validation support for accuracy. Key features include visual and auditory feedback, with an injection start force of ≤10 N (up to 60 IU).
TSA Disposable Pen Injector
The TSA variant is an internal-rotation type pen with no outward-extending components during dose adjustment. Its design ensures dosage cannot exceed the remaining volume in the cartridge, and it is manufactured within a 100,000-class cleanroom environment.
Prefilled Automatic Pen Injector Assembly (Two-Step and Three-Step)
These are disposable, spring-driven auto-injection devices developed to address needle anxiety and manual force limitations experienced by patients. Safety is supported through a hidden needle, while compliance is reinforced by an automatic locking shield that engages after injection.
Reusable Pen Injector
For long-term therapy, the Reusable Pen Injector supports replaceable cartridges and is rated for a 3,000+ cycle lifecycle, with flexibility to support both IU and mg scaling.
The broader line also includes the SP Disposable Pen Injector, Self-locking Pen Injector (100 IU), and Disposable Fixed-dose Pen Injector, rounding out a portfolio intended to match varied clinical dosing requirements.
Manufacturing Infrastructure Supporting Clinical-Grade Assembly
Behind these devices sits a substantial manufacturing footprint: 10,600 m² of Class 100,000 cleanrooms, 3,600 m² of Class 10,000 cleanrooms, and a dedicated 2,300 m² pen injector workshop. Quality oversight is maintained by a 76-person specialized quality team, while a 50-person mold maintenance team supports an independent mold center that has delivered over 300 precision molds to date. NEST maintains full lifecycle validation and batch traceability through batch numbers and retained samples, and its processes are compliant with RoHS and REACH regulations—factors directly relevant to any cartridge assembly intended for clinical use.
Certifications Enabling Global Clinical Deployment
NEST's cartridge and pen-injector product lines carry an extensive certification profile, including ISO 9001, ISO 13485, ISO 11137, ISO 15378, and IATF 16949, alongside CE MDR Certification and MDSAP Five-Country Certification covering the USA, Canada, Australia, Japan, and Brazil. In the United States, the company holds FDA 510(k) clearances (K240961, K240774) and US DMF filings (No. 40744, No. 42439, No. 40922). Additional regulatory coverage includes Canada Medical Device Licenses (No. 113733, No. 112619) and a China Class II Medical Device Certificate. These certifications have been audited by TÜV SÜD across ISO 9001, 13485, and 11137 standards, providing third-party validation for pharmaceutical companies evaluating pre-sterilized cartridge assembly partners for clinical-use programs.
One-Stop Service Model From Mold Design to Global Delivery
NEST operates a full in-house industry chain—from independent mold design and R&D through automated mass production and global logistics. The company also conducts Freedom to Operate (FTO) analysis across major markets including China, the US, the UK, and Europe, helping mitigate patent risk for clients integrating pre-sterilized cartridges into pen-injector assemblies. Its service scope covers pre-sales customization, technical validation, automated assembly line planning, and global logistics, supported by integrated warehousing in the US (Woodbridge, NJ and Phoenix, AZ), Europe (Hendrik-Ido-Ambacht, Netherlands), the Middle East (Sharjah, UAE), Japan (Yokohama), and Turkey (Istanbul), which helps shorten lead times for international clinical supply chains. NEST has also partnered with global pharmaceutical companies for final device assembly and drug-device combination validation, reflecting an ecosystem approach to bringing pre-sterilized cartridge and pen-injector solutions to market.
A Coordinated Approach to Clinical-Use Pen-Injector Assembly
Taken together, NEST's combination of borosilicate RTU Cartridges, cross-linked siliconization technology, SAL 10⁻⁶ moist heat sterilization, and a multi-format pen-injector lineup gives pharmaceutical manufacturers a coordinated pathway from cartridge production to finished, pre-sterilized pen-injector assembly. For companies serving insulin, GLP-1, and FSH markets—or research institutions and hospitals requiring validated drug-device combinations—the breadth of certifications, cleanroom capacity, and integrated global logistics positions Wuxi NEST Biotechnology Co., Ltd. as a documented option for clinical-use pre-sterilized cartridge assembly programs.
https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.
+ There are no comments
Add yours